MedTrace Logo

Liposomal Bupivacaine in Total Knee Arthroplasty

NCT03541265 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-05-30

No results posted yet for this study

Summary

Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.

Conditions

Interventions

DRUG

Exparel

long-acting Bupivacaine extended release liposome compound

PROCEDURE

Adductor block protocol

Adductor block using Exparel

PROCEDURE

peri-articular injection protocol

peri-articular injection using Exparel

Sponsors & Collaborators

  • Bronx-Lebanon Hospital Center Health Care System

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2017-06-01
Completion
2018-03-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03541265 on ClinicalTrials.gov